Table 1 Clinical and histological characteristics of the primary cohort
Variable | LVI- (n = 92) | LVI+ (n = 68) | P+ | OR (95% CI) | P value |
|---|---|---|---|---|---|
Gender | 1+ | ||||
male | 63 (68.5) | 46 (67.6) | 1 | ||
female | 29 (31.5) | 22 (32.4) | 1.04 (0.527~2.03) | 0.91 | |
Age | 0.5+ | ||||
≤60 | 37 (40.2) | 32 (47.1) | 1 | ||
>60 | 55 (59.8) | 36 (52.9) | 0.757 (0.40~1.43) | 0.39 | |
T stage | < 0.001+ | ||||
T1 | 20 (21.7) | 0 (0.0) | / | ||
T2 | 11 (12.0) | 5 (7.4) | 1 | ||
T3 | 42 (45.0) | 31 (47.1) | 1.62 (0.51~5.15) | 0.411 | |
T4 | 19 (20.7) | 32 (47.1) | 3.71 (1.12~12.30) | 0.032 | |
N stage | < 0.001+ | ||||
N0 | 42 (45.7) | 6 (8.8) | 1 | ||
N1 | 21 (22.8) | 10 (14.7) | 3.33 (1.07~10.4) | 0.04 | |
N2 | 16 (17.4) | 18 (26.5) | 7.87 (2.65~23.4) | < 0.001 | |
N3 | 13 (14.1) | 34 (50.0) | 18.31 (6.29~53.3) | < 0.001 | |
AJCC stage | < 0.001+ | ||||
I | 23 (25) | 1 (1.5) | 1 | ||
II | 35 (38.0) | 10 (14.7) | 6.57 (0.79~54.8) | 0.08 | |
III | 33 (35.9) | 54 (79.4) | 37.64 (4.8~291.8) | < 0.001 | |
IV | 1 (1.1) | 3 (4.4) | 69 (3.36~1415.9) | 0.006 | |
Tumor differentiation | 0.1+ | ||||
Poor | 48 (52.2) | 45 (66.2) | 1 | ||
moderate | 44 (47.8) | 23 (33.8) | 0.558 (0.29~1.06) | 0.077 | |
CEA | 1+ | ||||
≤ 5 ng/mL | 81 (88.0) | 59 (86.8) | 1 | ||
> 5 ng/mL | 11 (12.0) | 9 (13.2) | 1.12 (0.43~2.89) | 0.809 | |
CA199 | 1+ | ||||
≤ 37.0 U/mL | 81 (88.0) | 60 (88.2) | 1 | ||
> 37.0 U/mL | 11 (12.0) | 8 (11.8) | 0.98 (0.36~2.57) | 0.970 | |
A-Radscore, median (range) | −0.4 (−5.2~1.4) | 0.4 (−2.8~1.9) | < 0.001# | 2.42 (1.62~3.6) | < 0.001 |
V-Radscore, median (range) | −0.2 (− 26.5~2.1) | 0.2 (−2.9~6.1) | < 0.001# | 1.85 (1.13~3.01) | 0.002 |
A + V-Radscore, median (range) | −0.7 (−5.0~2.1) | 0.6 (−3.0~2.1) | < 0.001# | 2.29 (1.64~3.19) | < 0.001 |